These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 26414070)

  • 1. CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.
    Devapatla B; Sharma A; Woo S
    PLoS One; 2015; 10(9):e0139237. PubMed ID: 26414070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling.
    Wang H; Zhang C; Chi H; Meng Z
    Int J Oncol; 2018 Jun; 52(6):2051-2060. PubMed ID: 29620259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
    Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
    Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquired Resistance with Epigenetic Alterations Under Long-Term Antiangiogenic Therapy for Hepatocellular Carcinoma.
    Ohata Y; Shimada S; Akiyama Y; Mogushi K; Nakao K; Matsumura S; Aihara A; Mitsunori Y; Ban D; Ochiai T; Kudo A; Arii S; Tanabe M; Tanaka S
    Mol Cancer Ther; 2017 Jun; 16(6):1155-1165. PubMed ID: 28246302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option.
    Smolle E; Taucher V; Petru E; Haybaeck J
    Anticancer Res; 2014 Apr; 34(4):1519-30. PubMed ID: 24692678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCR2-Expressing Tumor Cells Drive Vascular Mimicry in Antiangiogenic Therapy-Resistant Glioblastoma.
    Angara K; Borin TF; Rashid MH; Lebedyeva I; Ara R; Lin PC; Iskander A; Bollag RJ; Achyut BR; Arbab AS
    Neoplasia; 2018 Oct; 20(10):1070-1082. PubMed ID: 30236892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
    Huang M; Chen C; Geng J; Han D; Wang T; Xie T; Wang L; Wang Y; Wang C; Lei Z; Chu X
    Cancer Lett; 2017 Jul; 398():12-21. PubMed ID: 28377178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study.
    Scartozzi M; Faloppi L; Svegliati Baroni G; Loretelli C; Piscaglia F; Iavarone M; Toniutto P; Fava G; De Minicis S; Mandolesi A; Bianconi M; Giampieri R; Granito A; Facchetti F; Bitetto D; Marinelli S; Venerandi L; Vavassori S; Gemini S; D'Errico A; Colombo M; Bolondi L; Bearzi I; Benedetti A; Cascinu S
    Int J Cancer; 2014 Sep; 135(5):1247-56. PubMed ID: 24510746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice.
    Liu X; Peng J; Sun W; Yang S; Deng G; Li F; Cheng JW; Gordon JR
    Tohoku J Exp Med; 2012 Oct; 228(2):147-56. PubMed ID: 23019013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NSK-01105, a novel sorafenib derivative, inhibits human prostate tumor growth via suppression of VEGFR2/EGFR-mediated angiogenesis.
    Yu P; Ye L; Wang H; Du G; Zhang J; Zuo Y; Zhang J; Tian J
    PLoS One; 2014; 9(12):e115041. PubMed ID: 25551444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK.
    Zhai B; Zhang X; Sun B; Cao L; Zhao L; Li J; Ge N; Chen L; Qian H; Yin Z
    Tumour Biol; 2016 Jun; 37(6):8047-55. PubMed ID: 26711788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining TMZ and SB225002 induces changes of CXCR2 and VEGFR signalling in primary human endothelial cells
    Urbantat RM; Jelgersma C; Vajkoczy P; Brandenburg S; Acker G
    Oncol Rep; 2022 Sep; 48(3):. PubMed ID: 35856448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma.
    Tovar V; Cornella H; Moeini A; Vidal S; Hoshida Y; Sia D; Peix J; Cabellos L; Alsinet C; Torrecilla S; Martinez-Quetglas I; Lozano JJ; Desbois-Mouthon C; Solé M; Domingo-Domenech J; Villanueva A; Llovet JM
    Gut; 2017 Mar; 66(3):530-540. PubMed ID: 26658144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IKKβ Regulates VEGF Expression and Is a Potential Therapeutic Target for Ovarian Cancer as an Antiangiogenic Treatment.
    Kinose Y; Sawada K; Makino H; Ogura T; Mizuno T; Suzuki N; Fujikawa T; Morii E; Nakamura K; Sawada I; Toda A; Hashimoto K; Isobe A; Mabuchi S; Ohta T; Itai A; Morishige K; Kurachi H; Kimura T
    Mol Cancer Ther; 2015 Apr; 14(4):909-19. PubMed ID: 25637316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a metalloprotease-chemokine signaling system in the ovarian cancer microenvironment: implications for antiangiogenic therapy.
    Agarwal A; Tressel SL; Kaimal R; Balla M; Lam FH; Covic L; Kuliopulos A
    Cancer Res; 2010 Jul; 70(14):5880-90. PubMed ID: 20570895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft--no benefit of combination therapy.
    Wehler TC; Hamdi S; Maderer A; Graf C; Gockel I; Schmidtmann I; Hainz M; Berger MR; Theobald M; Galle PR; Moehler M; Schimanski CC
    Int J Colorectal Dis; 2013 Mar; 28(3):385-98. PubMed ID: 22983756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The CXCL7/CXCR1/2 axis is a key driver in the growth of clear cell renal cell carcinoma.
    Grépin R; Guyot M; Giuliano S; Boncompagni M; Ambrosetti D; Chamorey E; Scoazec JY; Negrier S; Simonnet H; Pagès G
    Cancer Res; 2014 Feb; 74(3):873-83. PubMed ID: 24335961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
    Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.
    Gao DY; Lin TsT; Sung YC; Liu YC; Chiang WH; Chang CC; Liu JY; Chen Y
    Biomaterials; 2015 Oct; 67():194-203. PubMed ID: 26218745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib and thyroid cancer.
    Fallahi P; Ferrari SM; Santini F; Corrado A; Materazzi G; Ulisse S; Miccoli P; Antonelli A
    BioDrugs; 2013 Dec; 27(6):615-28. PubMed ID: 23818056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.